Alzheimer's Archives

News and Trends 26 Dec 2016

The Largest Deals, Fundraising and Exits of 2016 in European Biotech

Curious about which technologies have attracted the most cash in biotech finance this year? Here’s a list of the most impressive cash movements of 2016 in Europe. Believe it or not, 2016 has been the worst year for biotech finance in a decade. The political scene has become unfavorable for British biotech after Brexit, and the uncertainty raised by […]

December 26, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Dec 2016

The 8 Biggest Biotech Medical Fails of 2016 in Europe

Although 2016 has brought plenty of good news in medical advances, biotech is an industry where failure is part of the game. Here’s a list of medical fails in biotech to learn from this year. Unfortunately, 2016 has not been a good year for pharma, with revenues in the top companies falling, the lowest number […]

December 23, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Dec 2016

What Does ‘Anti-Aging Treatment’ Mean in Biotech?

Beyond filling in wrinkles with cosmetics, how do you solve a problem like aging? Here’s how biotech is sinking its teeth into the challenge. “Aging is… broadly [defined] as the time-dependent functional decline that affects most living organisms.” Maria Blasco, Hallmarks of Aging. Can we treat aging directly with medicine? “For the past decade, pharma and […]

December 20, 2016 - 5 minutesmins - By Evelyn Warner

News and Trends 19 Dec 2016

Evotec closes the year partnering with Celgene to treat Alzheimer’s

Evotec is closing a fantastic financial year with another top-level partnership; Celgene has decided to trust in its iPSC platform to develop drugs for neurodegenerative diseases. Evotec is a successful drug discovery CRO based in Germany that has managed to sign partnerships with some of the biggest names in Biotech. In addition to previous deals with Bayer, Merck, […]

December 19, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Dec 2016

Following Eli Lilly’s Failure, what’s Next in Alzheimer’s Treatments?

Hopes for an Alzheimer’s cure took a hit with Eli Lilly’s recent failure, but it’s not over yet. Probiodrug explains the failure and response. Alzheimer’s Disease devastates families and represents one of the largest financial burdens in society. Now the sixth leading cause of death for all age groups, the neurodegenerative disease cost the US […]

December 19, 2016 - 7 minutesmins - By Evelyn Warner

News and Trends 30 Nov 2016

Drugging the Undruggable: New Acquisition to Boost GPCR Drugs

Heptares Therapeutics has acquired G7 Therapeutics to take control over its GPCR technology, boost its pipeline and keep competitors in this profitable field at bay. Heptares Therapeutics develops therapies directed to G protein-coupled receptors (GPCRs), a large family of hot but elusive targets for biopharma. The British company, owned by the Japanese Sosei, just announced it […]

November 30, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 17 Oct 2016

Meet the First Biotech to Jump on Autophagy After This Years’ Nobel Prize

Just after the Nobel Prize was awarded to the study of autophagy, PhoreMost announces a collaboration to target the process in neurodegenerative diseases. PhoreMost is a drug discovery company that focuses on finding ‘undruggable’ targets, such as the KRAS cancer gene. Now, the company has announced a collaboration with the University of Cambridge to start working […]

October 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 11 Oct 2016

World Mental Health Day: How is Biotech Helping the Cause?

Biotech is one of the main forces driving the development of effective therapies to treat neurological and mental disorders. For World Mental Health Day yesterday, we want to share with you some of the latest technologies that address these conditions. Yesterday, October 10th, was World Mental Health Day: it is dedicated to raising awareness of neurological and mental disorders […]

October 11, 2016 - 4 minutesmins - By Clara Rodríguez Fernández

synapses neurons alzheimers Bruce Rolff fi

News and Trends 27 Sep 2016

Another “Almost” against Alzheimers: Lundbeck’s Phase III Flop

Alzheimer’s Disease is the most common form of dementia, affecting 15M people across the world. With the most recent failure of idalopirdine, a cure will remain elusive for now. As Derek Lowe observes, “Alzheimers therapies have, for the most part, been a cliff over which people push bales of money.” Unfortunately, the late-stage failure of […]

September 27, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 26 Sep 2016

UPDATE: AC Immune rakes in €52.5M IPO for assault on Alzheimers

It’s not the $700M headlines imply, but AC Immune is winding up to make a splashy IPO of €52.5M to establish itself in the Alzheimer’s Disease space. You might have read about AC Immune‘s ‘$700M IPO’ and thought, “gee, that can’t be right – that sum is roughly half of the total from all European companies […]

September 26, 2016 - 2 minutesmins - By Evelyn Warner

taurx tau protein tangles biotech alzheimers

News and Trends 28 Jul 2016

World first Drug to ‘dissolve’ Tau-tangles in Alzheimer’s has Phase III Results

The much-anticipated results of TauRx’s Phase III trial for Alzheimer’s disease have finally been disclosed. Despite some complicated effects, this could be the first available working therapy for Alzheimer’s patients. According to the WHO, Alzheimer’s disease is the cause of up to 70% of dementia cases, which translates to over 30 million patients worldwide. As the world population ages, Alzheimer’s […]

July 28, 2016 - 3 minutesmins - By Denise Neves Gameiro

pharnext marie tooth disease IPO pharnext

News and Trends 14 Jul 2016

French Biotech that makes Drugs faster and cheaper IPO’s for €31M

Pharnext has successfully completed its IPO on the Euronext Paris exchange, allowing it to move forward with Phase II and III trials for Neurological diseases that include Alzheimer’s. Based in Paris, Pharnext is developing new therapies for neurological conditions, including rare diseases such as Charcot-Marie-Tooth Disease. New partners to join this biotech in the €31M IPO include Galapagos […]

July 14, 2016 - 2 minutesmins - By Dani Bancroft

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us